1 dney but did not have splenectomy or receive recombinant erythropoietin.

2                    All animals also received recombinant erythropoietin.

3 ombosis in patients receiving large doses of recombinant erythropoietin.

4 eating anemia in heart failure patients with recombinant erythropoietin and intravenous iron.

5 delivery of dialysis, correcting anemia with recombinant erythropoietin, and controlling the degree o

6                                              Recombinant erythropoietin (EPO) analogs [erythropoiesis

7                    Regular administration of recombinant erythropoietin (EPO) in patients with chroni

8                                              Recombinant erythropoietin (EPO) was introduced into cli

9 antially in their response to treatment with recombinant erythropoietin (EPO).

10                                              Recombinant erythropoietin is expensive and has been lin

11 elivery while awaiting the maximal effect of recombinant erythropoietin on bone marrow red blood cell

12   All patients either had had no response to recombinant erythropoietin or had a high endogenous eryt

13                                              Recombinant erythropoietin (rHuEPO, Epogen, Procrit), by

14 t because of increasing safety concerns that recombinant erythropoietin therapy for treating anemia m

15                                Topical human recombinant erythropoietin was applied to encourage angi

16                            Intravenous human recombinant erythropoietin was continued postoperatively

17                                        Human recombinant erythropoietin was first cloned in 1985, and

18 e utility of these yeast strains, functional recombinant erythropoietin was produced.